Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) is a global biopharmaceutical company focused on innovative research and development of proprietary drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. Sucampo has a marketed product - AMITIZA® - and a pipeline including lifecycle management and clinical development programs. Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the United Kingdom.

Rockville, US
159 (est)+99%
Sucampo Pharmaceuticals was founded in 1996 and is headquartered in Rockville, US

Sucampo Pharmaceuticals Locations

Rockville, US
Kita Ward, JP
Zug, CH
Chiyoda, JP
Chuo Ward, JP
Sanda-shi, JP
Milton, GB

Sucampo Pharmaceuticals Metrics

Sucampo Pharmaceuticals Summary

Market capitalization

$535 M

Closing share price

Sucampo Pharmaceuticals's current market capitalization is $535 M.

Sucampo Pharmaceuticals Financials

Sucampo Pharmaceuticals's revenue is $153 M in FY, 2015 which is 32.68% increase from the previous period.
FY, 2013FY, 2014FY, 2015


$89.6 M$115 M$153 M

Gross profit

$77.2 M$99.2 M$116 M

Operating income

$9.2 M$27.2 M$44.5 M

Operating expense total

$68 M$72 M$72 M

Net Income

$6.42 M$13.1 M$33.4 M

Operating cash flow

$-7.92 M$27.5 M$36.7 M

    Sucampo Pharmaceuticals Market Value History

    Sucampo Pharmaceuticals Online Presence

    Sucampo Pharmaceuticals News

    Sucampo Pharmaceuticals Company Life

    You may also be interested in